Get unlimited Pharma PLUS subscriptions for one low fixed rate with a FirstWord country license.
Click here for more details.
Click here for more details.
Don't Miss
The move by pharma into mHealth and apps has been slow, but according to the latest research from FirstWord Dossier, it is gaining speed. Download Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs to learn how your firm can effectively exploit the opportunities of the digital age. Learn more.
Insight, Analysis and Views
Most Popular
- Actavis to buy Warner Chilcott for $8.5 billion
- Physician Views Poll Results – Pfizer's Xeljanz appears to be lacking traction in US market, while EU regulatory rejection is having some impact on prescribing trends
- Lundbeck, Takeda present positive data from late-stage studies of depression drug Brintellix
- ViewPoints: Novartis' Sandoz unit moves biosimilar Enbrel into Phase III testing – extrapolation issues highlighted once again
- ViewPoints: Combination use beckons for Bayer's newly approved prostate treatment Xofigo say experts, if radioactivity concerns can be overcome
My News
Upgrade your subscription to get more features!